These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 8510937)

  • 41. Activation of gene expression by a non-transforming unmyristylated-SH3-deleted mutant of Src is dependent upon Tyr-527.
    Curto M; Carrero A; Frankel P; Foster DA
    Biochem Biophys Res Commun; 1997 Oct; 239(3):681-7. PubMed ID: 9367828
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design of an encodable tyrosine kinase-inducible domain: detection of tyrosine kinase activity by terbium luminescence.
    Zondlo SC; Gao F; Zondlo NJ
    J Am Chem Soc; 2010 Apr; 132(16):5619-21. PubMed ID: 20361796
    [TBL] [Abstract][Full Text] [Related]  

  • 43. c-ABL tyrosine kinase activity is regulated by association with a novel SH3-domain-binding protein.
    Zhu J; Shore SK
    Mol Cell Biol; 1996 Dec; 16(12):7054-62. PubMed ID: 8943360
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Highly conserved amino acids in the SH2 and catalytic domains of v-src are altered in naturally occurring, transformation-defective alleles.
    Verderame MF; Varmus HE
    Oncogene; 1994 Jan; 9(1):175-82. PubMed ID: 8302576
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Growth inhibition by Abl requires an interplay of its SH2 and tyrosine kinase domains.
    Mattioni T; Mayer BJ; Picard D
    FEBS Lett; 1996 Jul; 390(2):170-4. PubMed ID: 8706852
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tyrosine phosphorylation in the SH3 domain disrupts negative regulatory interactions within the c-Abl kinase core.
    Chen S; O'Reilly LP; Smithgall TE; Engen JR
    J Mol Biol; 2008 Nov; 383(2):414-23. PubMed ID: 18775435
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein.
    Weiner DB; Kokai Y; Wada T; Cohen JA; Williams WV; Greene MI
    Oncogene; 1989 Oct; 4(10):1175-83. PubMed ID: 2571965
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity.
    Dai Z; Pendergast AM
    Genes Dev; 1995 Nov; 9(21):2569-82. PubMed ID: 7590236
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Point mutation at single tyrosine residue of novel oncogene NOK abrogates tumorigenesis in nude mice.
    Chen Y; Li YH; Chen XP; Gong LM; Zhang SP; Chang ZJ; Zhang XF; Fu XY; Liu L
    Cancer Res; 2005 Dec; 65(23):10838-46. PubMed ID: 16322230
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cell cycle-regulated binding of c-Abl tyrosine kinase to DNA.
    Kipreos ET; Wang JY
    Science; 1992 Apr; 256(5055):382-5. PubMed ID: 1566087
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The C-terminus of c-ABL is required for proliferation and viability signaling in a c-ABL/erythropoietin receptor fusion protein.
    Okuda K; D'Andrea A; Van Etten RA; Griffin JD
    Blood; 1998 Nov; 92(10):3848-56. PubMed ID: 9808578
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of a small region of the v-fos gene product that is sufficient for transforming potential and growth-stimulating activity.
    Yoshida T; Shindo Y; Ohta K; Iba H
    Oncogene Res; 1989; 5(2):79-89. PubMed ID: 2514403
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oncogenic activation of c-ABL by mutation within its last exon.
    Goga A; McLaughlin J; Pendergast AM; Parmar K; Muller A; Rosenberg N; Witte ON
    Mol Cell Biol; 1993 Aug; 13(8):4967-75. PubMed ID: 8336729
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Conservation of function of Drosophila melanogaster abl and murine v-abl proteins in transformation of mammalian cells.
    Holland GD; Henkemeyer MJ; Kaehler DA; Hoffmann FM; Risser R
    J Virol; 1990 May; 64(5):2226-35. PubMed ID: 2157882
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structure and function of the Abelson murine leukemia virus transforming gene.
    Wang JY; Prywes R; Baltimore D
    Prog Clin Biol Res; 1983; 119():57-63. PubMed ID: 6306691
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structure-function analysis of SH3 domains: SH3 binding specificity altered by single amino acid substitutions.
    Weng Z; Rickles RJ; Feng S; Richard S; Shaw AS; Schreiber SL; Brugge JS
    Mol Cell Biol; 1995 Oct; 15(10):5627-34. PubMed ID: 7565714
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bone marrow B lymphocyte development in c-abl-deficient mice.
    Hardin JD; Boast S; Schwartzberg PL; Lee G; Alt FW; Stall AM; Goff SP
    Cell Immunol; 1995 Oct; 165(1):44-54. PubMed ID: 7671324
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential.
    Franz WM; Berger P; Wang JY
    EMBO J; 1989 Jan; 8(1):137-47. PubMed ID: 2496972
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Modifications of tumor histology by point mutations in the v-fps oncogene: possible role of extracellular matrix.
    Auersperg N; Pawson T; Worth A; Weinmaster G
    Cancer Res; 1987 Dec; 47(23):6341-8. PubMed ID: 3315185
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity.
    Shi Y; Alin K; Goff SP
    Genes Dev; 1995 Nov; 9(21):2583-97. PubMed ID: 7590237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.